GSK

AHF Urges Trinidad and Tobago to Sidestep Greedy GSK

Retrieved on: 
Friday, March 15, 2024
AIDS, Public Policy, Government, Health, Infectious Diseases, Advocacy Group Opinion, Pharmaceutical, ARV, GSK, HIV, COVID-19, AHF, Caribbean region of Colombia, Letter, AIDS Healthcare Foundation, Face, Biosimilar, Pharmaceutical industry

AIDS Healthcare Foundation (AHF) is calling on the government of Trinidad and Tobago to consider issuing a compulsory license for Tivicay (dolutegravir), a GSK antiretroviral (ARV) drug that treats HIV, which currently costs 25 times more than available biosimilar generics in neighboring Caribbean countries.

Key Points: 
  • AIDS Healthcare Foundation (AHF) is calling on the government of Trinidad and Tobago to consider issuing a compulsory license for Tivicay (dolutegravir), a GSK antiretroviral (ARV) drug that treats HIV, which currently costs 25 times more than available biosimilar generics in neighboring Caribbean countries.
  • In February, AHF and the Medical Research Foundation of Trinidad & Tobago sent a letter to GSK CEO Dame Emma Walmsley, which in part stated, “We urge you to address the lack of access to the antiretroviral drug Tivicay in Trinidad due to its high cost by lowering its price in line with biosimilar generics available in the Caribbean Region – or by committing not to threaten legal action against the purchase of a generic version of Tivicay.”
    To date, GSK has yet to respond to the letter.
  • Currently, Tivicay is under patent protection in Trinidad and Tobago, and GSK has threatened legal action if the country decides to import affordable generic ARVs.
  • “As a small island nation, Trinidad and Tobago is still recovering from the economic and social consequences of COVID-19 – paying 25 times more to provide lifelong HIV treatment for its people is untenable,” said AHF President Michael Weinstein.

Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors

Retrieved on: 
Tuesday, March 12, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Metabolism, GSK plc, Pharmacy, GSK, Cornell University, Patient, Acquisition, Marker, University, Biology, MBA, Agilent Technologies, Research and development, Therapy, Takeda, Patient safety, TYK2, Vaccine, Human, Pharmaceutical industry

Nimbus Therapeutics , LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine, today announced that Katharine Knobil, M.D., has been appointed to the Company’s Board of Directors.

Key Points: 
  • Nimbus Therapeutics , LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine, today announced that Katharine Knobil, M.D., has been appointed to the Company’s Board of Directors.
  • “We are honored to welcome Dr. Knobil to our Board of Directors as we embark on the next exciting chapter at Nimbus with plans to accelerate and expand our development programs in multiple therapeutic areas including oncology, immunology, and metabolism.
  • Dr. Knobil is currently a member of the Board of Directors at Marker Therapeutics (NASDAQ: MRKR) and Pliant Therapeutics (NASDAQ: PLRX).
  • “Nimbus has built a robust R&D organization that has demonstrated continued success in advancing promising discovery-stage science to product development.

Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team

Retrieved on: 
Tuesday, April 2, 2024
Science, Teva Pharmaceuticals, GSK, Executive, Inflammation, Patient, Knowledge, MD, Cough, Drug, Trevi, IPF, Idiopathic pulmonary fibrosis, Medical school, RCC, Therapy, Chronic cough, Pharmaceutical industry

NEW HAVEN, Conn., April 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of Margaret Garin, MD, MSCR, as Vice President of Clinical Development. Dr. Garin will be responsible for progressing the clinical development of Haduvio in chronic cough and brings unique and relevant experience from her previous lead role in clinical development at Bellus Health.

Key Points: 
  • Dr. Garin will be responsible for progressing the clinical development of Haduvio in chronic cough and brings unique and relevant experience from her previous lead role in clinical development at Bellus Health.
  • Her background spans various stages of the clinical development process including both strategic and executional roles, as well as the science of cough.
  • "I am happy to welcome Meg to our team," said David Clark, Chief Medical Officer of Trevi Therapeutics.
  • I am thrilled to have the ability to continue my work in chronic cough by joining the Trevi team to further the development of Haduvio for these patients."

William Thomas Digital Embarks on Next Phase of Growth with Strategic Leadership Additions

Retrieved on: 
Friday, March 22, 2024
Microsoft, CRM, Val, Growth, IKEA, Volkswagen, GSK, WTD, Marketing, No Fixed Address, CSO, President's Choice Financial, Management

TORONTO, March 22, 2024 /CNW/ - William Thomas Digital Inc. (WTD), a leading agency in personalized customer experiences, is happy to announce a series of strategic leadership changes designed to fuel its ambitious growth plans and reinforce its industry-leading position in CX marketing.

Key Points: 
  • TORONTO, March 22, 2024 /CNW/ - William Thomas Digital Inc. (WTD), a leading agency in personalized customer experiences, is happy to announce a series of strategic leadership changes designed to fuel its ambitious growth plans and reinforce its industry-leading position in CX marketing.
  • His prior role as CSO at Wunderman Thompson Canada underscores his experience and ability to drive strategic innovation at the highest levels.
  • Kevin's vision and leadership will be instrumental in further advancing WTD's mission to lead the industry in delivering data-driven, personalized customer experiences.
  • These strategic leadership changes underscore WTD's dedication to excellence, innovation, and its vision for the future, affirming the agency's position at the forefront of the personalized customer experience industry.

Advances in Digitalization Presented at the 10th Annual Genedata Biopharma Partner Symposium

Retrieved on: 
Thursday, March 21, 2024
AbbVie, Peptide, ChromeOS, Automation, Sanofi, Organization, Canadian Aviation Regulations, AstraZeneca, Novo Nordisk, MAM, Novartis, GSK, Boehringer Ingelheim, UCB, Vivisection, Roche, NGS, RNA, Knowledge, Merck, Hyphen, Spacecraft, Janssen, Daiichi Sankyo, Digitization, Novozymes, Fine chemical

BASEL, Switzerland, March 21, 2024 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the successful conclusion of the 10th Annual Genedata Biopharma Partner Symposium, held over 2 days from March 6–7, 2024 in Basel, Switzerland. This year's event marked the tenth year of bringing together Genedata customers to share best practices and demonstrate how they increase efficiency and productivity across entire organizations by leveraging the Genedata Biopharma Platform.

Key Points: 
  • BASEL, Switzerland, March 21, 2024 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the successful conclusion of the 10th Annual Genedata Biopharma Partner Symposium, held over 2 days from March 6–7, 2024 in Basel, Switzerland.
  • The Genedata Biopharma Partner Symposium has firmly established itself as a community platform to exchange pioneering work in digitalizing biopharma R&D and establishing best practices based on the Genedata software platform.
  • "The Genedata Biopharma Partner Symposium has firmly established itself as a community platform to exchange pioneering work in digitalizing biopharma R&D and establishing best practices based on the Genedata software platform.
  • The record participation this year underscores the leading position of the Genedata Biopharma Platform within the biopharma industry," said Othmar Pfannes, Ph.D., CEO of Genedata.

INSTITUTE FOR SUPPLY MANAGEMENT® HONORS 30 UNDER 30 RISING SUPPLY CHAIN STARS

Retrieved on: 
Wednesday, March 20, 2024
Titan, Government, Wavre, Organization, U.S. Steel, GSC, Shell, Rauf, GSK, Cox Communications, Metal, Public expenditure, Apex, MBA, MPA, Student, Woman, PMP, Engineering, Fluor Corporation, Johnson & Johnson, ISM, Shell plc, Geography, Northrop Grumman, Shell USA, Management

Now in its tenth year, the ISM program honors individuals who are 30 or younger and demonstrate leadership, innovation, collaboration, and other outstanding attributes--at work and through their professional associations. Intended to help bridge the talent gap in procurement and supply management for younger generations, the program highlights role models for aspiring supply chain practitioners and students.

Key Points: 
  • TEMPE, Ariz., March 20, 2024 /PRNewswire/ -- The Institute for Supply Management® (ISM®) announced the winners of the 2023-2024 30 Under 30 Rising Supply Chain Stars Recognition Program to honor global emerging leaders across various industries and supply management disciplines.
  • The top nominee or "megawatt" winner from the 30 Under 30 is Zain Rauf, a supply chain lead for renewable fuels at Shell Oil Company.
  • Intended to help bridge the talent gap in procurement and supply management for younger generations, the program highlights role models for aspiring supply chain practitioners and students.
  • "The latest 30 Under 30 winners exemplify the new generation of supply chain leadership and demonstrate how high performers can make an impact on the profession," said Derry.

Trialbee's Jamie Goldfarb to Lead Discussion on Defining Success and Enhancing Collaboration in Clinical Trials at Patients as Partners in Clinical Research Conference

Retrieved on: 
Thursday, March 14, 2024
Honey, Goldfarb, Patient, Success, Partner, Food and Drug Administration, ROI, Digital, TIL, Pharmacy, GSK, Research, Participation, National Cancer Institute, Cancer, Medidata Solutions, Ecosystem, Melanoma, Food, FDA, Process optimization, Fireside chats, Pharmaceutical industry

CHAPEL HILL, N.C. and MALMÖ, Sweden, March 14, 2024 /PRNewswire-PRWeb/ -- Trialbee, the global leader in technology-driven patient recruitment for clinical trials, is honored that Director of Patient Recruitment Strategy Jamie Goldfarb will take center stage at the Patients as Partners in Clinical Research on March 20-22, in Philadelphia, PA.

Key Points: 
  • The session aims to strengthen relationships among sites, sponsors, and patients to deepen understanding and engagement.
  • "Many patients aren't aware that clinical trials present viable treatment opportunities, and if they do, their needs are often overlooked," Goldfarb said.
  • "By actively listening to patients, sponsors can gain invaluable insights and perspectives that lead to medical advances and improve countless lives."
  • The Patients as Partners in Clinical Research conference offers a unique opportunity to hear from pharmaceutical research and development leaders, Food and Drug Administration (FDA) representatives, and patient advocates on how patient involvement drives greater efficiencies in clinical research.

Calder Biosciences Inc. Publishes Next-Generation Vaccine Technology in Nature Communications

Retrieved on: 
Thursday, March 14, 2024
Health, Infection, GSK, Ageing, 3D, MD, RSV, Protein engineering, Antibody, Licensure, Respiratory syncytial virus, Vaccination, CSO, Vaccine, Paper, Animal, Nature Communications

BROOKLYN, N.Y., March 14, 2024 /PRNewswire/ -- Calder Biosciences, Inc ., a next-generation vaccine company, has been published in a Nature Communications article ( https://www.nature.com/articles/s41467-024-46295-8 ) that debuts and validates the application of Calder's '3D Vaxlock' platform technology.

Key Points: 
  • BROOKLYN, N.Y., March 14, 2024 /PRNewswire/ -- Calder Biosciences, Inc ., a next-generation vaccine company, has been published in a Nature Communications article ( https://www.nature.com/articles/s41467-024-46295-8 ) that debuts and validates the application of Calder's '3D Vaxlock' platform technology.
  • Application of the technology not only dramatically improves potency, but also improves shelf-life of the vaccine at refrigerated temperatures that will facilitate distribution and delivery.
  • In the Nature Communications manuscript, Calder demonstrates that a high dose of their RSV vaccine achieves responses in aged, immunosenescent animals equivalent to responses in the young animal control group.
  • Calder also plans to apply its technology more generally in protein engineering, imparting thermostability as needed to additional subunit vaccines, biologics, or other targets.

U.S. 1st Latino Tech Payroll Startup Trez.co, Announces Advisory Board of Industry Giants and C-Suite Executives As It Opens Its Scaling Seed Round

Retrieved on: 
Monday, March 11, 2024
CIO, Waste management, Growth, Mentorship, Box, GSK, JPMorgan Chase, Organizational founder, Central Waqf Council, UnitedHealth Group, Johnson & Johnson, Cisco, Stanford University, CMO, ADP, Corporation

SAN FRANCISCO, March 11, 2024 /PRNewswire/ --

Key Points: 
  • Trez.co, the first U.S. Latino payroll platform company in the United States, is proud to announce its Board of Advisors.
  • This initiative underscores Trez.co's commitment to driving national economic growth through customer first payroll, benefits, and financial solutions tailored to the unique needs of Latino businesses and employees.
  • "Trez is the successful outcome of conversations initiated from LBAN (latino business action network) at Stanford University.
  • Maria Eugenia brings vast corporate governance experience as she has led several boards as the chairman of the board.

4BIO Capital Strengthens Advisory Board and Investment Team

Retrieved on: 
Monday, March 11, 2024
Eli Lilly, University, Advisory board, AstraZeneca, Philosophy, Doctor of Philosophy, GSK, CSL, Growth, Sale, Government, Vaccine, Therapy, CSL Vifor, Associate, VVMF, Admiration, NSW, Pharmaceutical industry

LONDON, 11 March 2024 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm unlocking the treatments of the future by investing in advanced therapies and other emerging technologies, announces today the appointments of biopharmaceutical industry veteran Abbas Hussain and world-leading vectorology expert Leszek Lisowski, PhD MBA to its Advisory Board.

Key Points: 
  • LONDON, 11 March 2024 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm unlocking the treatments of the future by investing in advanced therapies and other emerging technologies, announces today the appointments of biopharmaceutical industry veteran Abbas Hussain and world-leading vectorology expert Leszek Lisowski, PhD MBA to its Advisory Board.
  • Along with the appointment of Abbas and Leszek, 4BIO is also pleased to announce the promotion of Dr Natalie Johnston to Principal.
  • I am honoured to be joining the 4BIO Capital Advisory Board alongside such esteemed members and look forward to working closely with the entire team to support the firm’s portfolio companies and identify the disruptive companies of the future.”
    Leszek Lisowski, newly appointed Advisory Board member added: “I have watched the 4BIO Capital team’s success over the last 8 years with admiration and I am excited to support them as an Advisory Board member.
  • Fostering the development of our team is core to 4BIO’s philosophy, ensuring we have the very best talent to help drive tomorrow’s innovation.